Literature DB >> 23027073

Surgical strategies for non-functioning pancreatic neuroendocrine tumours.

M J Kim1, D W Choi, S H Choi, J S Heo, H J Park, K K Choi, K-T Jang, J-Y Sung.   

Abstract

BACKGROUND: The purpose of this study was to identify management strategies for non-functioning pancreatic neuroendocrine tumours (NF-PNETs) by analysis of surgical outcomes at a single institution.
METHODS: Archived records of patients with NF-PNETs who underwent surgery between 1994 and 2010 were reviewed.
RESULTS: Among 125 patients, the median tumour size was 2·5 (range 0·15-20·5) cm. Of the 51 NF-PNETs with a diameter of no more than 2 cm, 12 (24 per cent) were diagnosed as carcinoma. Overall 20 patients (16·0 per cent) had metastases to the lymph nodes. The minimum size of the tumour with lymph node metastasis was 1·2 cm. Having a NF-PNET of 2 cm or larger significantly increased the probability of a poorly differentiated carcinoma (P = 0·006), and having a NF-PNET of at least 2·5 cm significantly increased the probability of lymph node metastasis (P = 0·048). The 5-year cumulative survival rate after curative resection was 89·7 per cent. During a median follow-up of 31·5 months, there were 27 recurrences (23·1 per cent) and 13 disease-specific deaths (11·1 per cent) among the 117 patients who had an R0 resection. All patients who underwent repeat operations were alive without additional recurrence after a mean(s.d.) follow-up of 27·1(18·0) months.
CONCLUSION: Curative surgery should be performed for control of primary NF-PNETs. Lymph node dissection for NF-PNETs of 2·5 cm or larger and at least node sampling for tumours with a diameter of 1 cm or more are recommended. Debulking surgery should be considered for advanced tumours.
Copyright © 2012 British Journal of Surgery Society Ltd. Published by John Wiley & Sons, Ltd.

Entities:  

Mesh:

Year:  2012        PMID: 23027073     DOI: 10.1002/bjs.8892

Source DB:  PubMed          Journal:  Br J Surg        ISSN: 0007-1323            Impact factor:   6.939


  14 in total

1.  Aspirin inhibits cell viability and mTOR downstream signaling in gastroenteropancreatic and bronchopulmonary neuroendocrine tumor cells.

Authors:  Matilde Spampatti; George Vlotides; Gerald Spöttl; Julian Maurer; Burkhard Göke; Christoph J Auernhammer
Journal:  World J Gastroenterol       Date:  2014-08-07       Impact factor: 5.742

Review 2.  Systematic Review and Metaanalysis of Lymph Node Metastases of Resected Pancreatic Neuroendocrine Tumors.

Authors:  Masayuki Tanaka; Max Heckler; André L Mihaljevic; Pascal Probst; Ulla Klaiber; Ulrike Heger; Simon Schimmack; Markus W Büchler; Thilo Hackert
Journal:  Ann Surg Oncol       Date:  2020-07-27       Impact factor: 5.344

3.  Clinical outcomes and prognostic factors of resected pancreatic neuroendocrine neoplasms: A single-center experience in China.

Authors:  Kaizhou Jin; Guopei Luo; Jin Xu; Bo Zhang; Chen Liu; Shunrong Ji; Liang Liu; Jiang Long; Quanxing Ni; Xianjun Yu
Journal:  Oncol Lett       Date:  2017-03-09       Impact factor: 2.967

4.  Predictive Value of Chromogranin A and a Pre-Operative Risk Score to Predict Recurrence After Resection of Pancreatic Neuroendocrine Tumors.

Authors:  Alexander V Fisher; Alexandra G Lopez-Aguiar; Victoria R Rendell; Courtney Pokrzywa; Flavio G Rocha; Zaheer S Kanji; George A Poultsides; Eleftherios A Makris; Mary E Dillhoff; Eliza W Beal; Ryan C Fields; Roheena Z Panni; Kamran Idrees; Paula Marincola Smith; Clifford S Cho; Megan V Beems; Shishir K Maithel; Emily R Winslow; Daniel E Abbott; Sharon M Weber
Journal:  J Gastrointest Surg       Date:  2019-01-18       Impact factor: 3.452

5.  Significance of lymph node metastasis in pancreatic neuroendocrine tumor.

Authors:  Katsunobu Taki; Daisuke Hashimoto; Shigeki Nakagawa; Nobuyuki Ozaki; Shinjiro Tomiyasu; Masaki Ohmuraya; Kota Arima; Takayoshi Kaida; Takaaki Higashi; Keita Sakamoto; Kazuya Sakata; Hirohisa Okabe; Hidetoshi Nitta; Hiromitsu Hayashi; Akira Chikamoto; Toru Beppu; Hiroshi Takamori; Masahiko Hirota; Hideo Baba
Journal:  Surg Today       Date:  2017-02-22       Impact factor: 2.549

6.  Short- and long-term outcomes of laparoscopic organ-sparing resection in pancreatic neuroendocrine tumors: a single-center experience.

Authors:  Javier A Cienfuegos; Joseba Salguero; Jorge M Núñez-Córdoba; Miguel Ruiz-Canela; Alberto Benito; Sira Ocaña; Gabriel Zozaya; Pablo Martí-Cruchaga; Fernando Pardo; José Luis Hernández-Lizoáin; Fernando Rotellar
Journal:  Surg Endosc       Date:  2017-01-26       Impact factor: 4.584

7.  Risk factors for lymph node metastasis in patients with pancreatic neuroendocrine neoplasms.

Authors:  Yosuke Nakao; Hiromitsu Hayashi; Yo-Ichi Yamashita; Ofuchi Takashi; Kazuki Matsumura; Norio Uemura; Fumimasa Kitamura; Rumi Itoyama; Toshihiko Yusa; Katsunobu Taki; Tatsunori Miyata; Takaaki Higashi; Shigeki Nakagawa; Hirohisa Okabe; Katsunori Imai; Hideo Baba
Journal:  World J Clin Oncol       Date:  2022-06-24

8.  Nonfunctional pancreatic neuroendocrine tumors <2 cm on preoperative imaging are associated with a low incidence of nodal metastasis and an excellent overall survival.

Authors:  Paul A Toste; Brian E Kadera; Sergei F Tatishchev; David W Dawson; Barbara M Clerkin; Raman Muthusamy; Rabindra Watson; James S Tomlinson; Oscar J Hines; Howard A Reber; Timothy R Donahue
Journal:  J Gastrointest Surg       Date:  2013-10-08       Impact factor: 3.452

9.  PROGNOSTIC FACTORS IN PATIENTS WITH SURGICAL RESECTION OF PANCREATIC NEUROENDOCRINE TUMOURS.

Authors:  S O Dima; T Dumitrascu; C Pechianu; R T Grigorie; V Brasoveanu; A Sorop; I Lupescu; R Purnichescu-Purtan; A Croitoru; N Bacalbasa; A Tanase; D R Tomescu; V Herlea; I Popescu
Journal:  Acta Endocrinol (Buchar)       Date:  2018 Jul-Sep       Impact factor: 0.877

10.  Behavior of Small, Asymptomatic, Nonfunctioning Pancreatic Neuroendocrine Tumors (NF-PNETs).

Authors:  Jae Gu Jung; Kyu Taek Lee; Young Sik Woo; Jong Kyun Lee; Kwang Hyuck Lee; Kee-Taek Jang; Jong Chul Rhee
Journal:  Medicine (Baltimore)       Date:  2015-07       Impact factor: 1.889

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.